NA Ataxia Market - Industry Trends and Forecast to 2029

Description

List of Tables

North America ataxia market is projected to register a substantial CAGR of 7.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

North America Ataxia Market, By Type (Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), Product (Treatment and Diagnosis), Dosage Form (Solid, Liquids, and Others), Route of Administration (Oral, Parenteral, and Others), Patient Type (Adult, Child, and Geriatric), End User (Hospital, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the North America ataxia market are:

Due to rapid research in the field of ataxia therapeutics

Growing number of incidences of auto-immune disease

Market Players

Some of the key market players in the North America ataxia market are listed below:

Novartis AG

Merck KGaA

Aurobindo Pharma.

Pfizer Inc.

Sanofi

Teva Pharmaceutical Industries Ltd.

Acorda Therapeutics, Inc.

Viatris Inc.

Sun Pharmaceutical Industries Ltd.

Lupin.

Amneal Pharmaceuticals LLC.

Apotex Inc.

Cipla Inc.

Biovista

Design Therapeutics Inc.

Reata Pharmaceuticals, Inc.

MATRIX BIOMED

Biohaven Pharmaceuticals

Retrotope Inc.

Adverum Biotechnologies, Inc.

Sutter Health.

Upstream Rehabilitation Inc.

Banner Health

Select Medical Corporation

ATI Physical Therapy

1 INTRODUCTION 67

1.1 OBJECTIVES OF THE STUDY 67
1.2 MARKET DEFINITION 67
1.3 OVERVIEW OF NORTH AMERICA ATAXIA MARKET 67
1.4 LIMITATIONS 69
1.5 MARKETS COVERED 69

2 MARKET SEGMENTATION 73

2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 CURRENCY AND PRICING 75
2.5 DBMR TRIPOD DATA VALIDATION MODEL 76
2.6 MULTIVARIATE MODELLING 79
2.7 TYPE LIFELINE CURVE 79
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 80
2.9 DBMR MARKET POSITION GRID 81
2.10 MARKET END USER COVERAGE GRID 82
2.11 VENDOR SHARE ANALYSIS 83
2.12 SECONDARY SOURCES 84
2.13 ASSUMPTIONS 84

3 EXECUTIVE SUMMARY 85

4 PREMIUM INSIGHTS 88

4.1 PESTEL 90
4.2 PORTER'S FIVE FORCES MODEL 91
4.3 EPIDEMIOLOGY 92

5 PIPELINE ANALYSIS 93

6 NORTH AMERICA ATAXIA MARKET: REGULATORY SCENARIO 95

7 MARKET OVERVIEW 98

7.1 DRIVERS 100
- 7.1.1 INCREASING PREVALENCE AND INCIDENCES OF ATAXIA 100
- 7.1.2 RAPID RESEARCH IN FIELD OF ATAXIA THERAPEUTICS 100
- 7.1.3 RISE IN ALCOHOL AND DRUG USAGE 100
- 7.1.4 GROWING NUMBER OF INCIDENCES OF AUTO-IMMUNE DISEASE 101
7.2 RESTRAINTS 101
- 7.2.1 DIFFICULTY IN DIAGNOSIS OF DISEASE 101
- 7.2.2 LACK OF GENETIC TESTING IN DEVELOPING COUNTRIES 102
7.3 OPPORTUNITIES 102
- 7.3.1 RISING HEALTHCARE EXPENDITURE 102
- 7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 102
7.4 CHALLENGES 103
- 7.4.1 STRINGENT RULES AND REGULATIONS 103
- 7.4.2 PRODUCT RECALL 104

8 NORTH AMERICA ATAXIA MARKET, BY TYPE 105

8.1 OVERVIEW 106
8.2 SPINOCEREBELLAR ATAXIAS 109
- 8.2.1 TYPE 3 110
- 8.2.2 TYPE 2 110
- 8.2.3 TYPE 1 110
- 8.2.4 OTHERS 110
8.3 ATAXIA-TELANGIECTASIA 110
8.4 EPISODIC ATAXIA 111
8.5 OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) 112

9 NORTH AMERICA ATAXIA MARKET, BY PRODUCT 114

9.1 OVERVIEW 115
9.2 TREATMENT 118
- 9.2.1 PHARMACOTHERAPY 119
  - 9.2.1.1 STIFFNESS/SPASTICITY 120
    - 9.2.1.1.1 GABAPENTIN 120
    - 9.2.1.1.2 LEVODOPA 120
    - 9.2.1.1.3 OTHERS 120
  - 9.2.1.2 GAIT AND TREMORS 121
    - 9.2.1.2.1 VARENICLINE 121
    - 9.2.1.2.2 RILUZOLE 121
    - 9.2.1.2.3 AMANTADINE 121
    - 9.2.1.2.4 OTHERS 121
  - 9.2.1.3 ANTI-OXIDANTS 121
    - 9.2.1.3.1 N-ACETYLCYSTEINE 122
    - 9.2.1.3.2 SELEGILINE 122
    - 9.2.1.3.3 DEHYDROEPIANDROSTERONE 122
    - 9.2.1.3.4 VITAMIN E 122
  - 9.2.1.4 NON ANTI-OXIDANTS 122
    - 9.2.1.4.1 ERYTHROPOIETIN 123
    - 9.2.1.4.2 DEFERIPRONE 123
    - 9.2.1.4.3 RESVERATROL 123
    - 9.2.1.4.4 HISTONE DEACETYLASE INHIBITORS 123
  - 9.2.1.5 ANTI-ARRHYTHMIC AGENTS 123
    - 9.2.1.5.1 AMIODARONE 124
    - 9.2.1.5.2 PROPAFENONE 124
    - 9.2.1.5.3 FLECAINIDE 124
    - 9.2.1.5.4 IBUTILIDE 124
  - 9.2.1.6 ANTI-CARDIAC FAILURE 124
    - 9.2.1.6.1 BENAZEPRIL 125
    - 9.2.1.6.2 LISINOPRIL 125
    - 9.2.1.6.3 CAPTOPRIL 125
    - 9.2.1.6.4 ENALAPRIL 125
    - 9.2.1.6.5 FOSINOPRIL 125
    - 9.2.1.6.6 MOEXIPRIL 125
    - 9.2.1.6.7 OTHERS 125
  - 9.2.1.7 ORAL HYPOGLYCEMIC THERAPEUTICS 126
    - 9.2.1.7.1 BIGUANIDES (METFORMIN) 126
    - 9.2.1.7.2 SULFONYLUREAS 126
    - 9.2.1.7.2.1 GLIPIZIDE 127
    - 9.2.1.7.2.2 GLIMEPIRIDE 127
    - 9.2.1.7.2.3 GLYBURIDE 127
    - 9.2.1.7.2.4 OTHERS 127
    - 9.2.1.7.3 THIAZOLIDINEDIONES 127
    - 9.2.1.7.4 MEGLITINIDES 127
- 9.2.2 LIFESTYLE THERAPY 127
  - 9.2.2.1 PHYSICAL THERAPY 128
  - 9.2.2.2 SPEECH THERAPY 128
  - 9.2.2.3 PALLIATIVE CARE 128
  - 9.2.2.4 OTHERS 128
- 9.2.3 SUPPORTIVE DEVICES 128
  - 9.2.3.1 WALKING AIDS 128
  - 9.2.3.2 WHEELCHAIRS 128
  - 9.2.3.3 OTHERS 128
9.3 DIAGNOSTICS 129
- 9.3.1 IMAGING TEST 130
  - 9.3.1.1 MRI SCAN 130
  - 9.3.1.2 OTHERS 130
- 9.3.2 BLOOD TEST 130
- 9.3.3 GENETIC TESTING 130

10 NORTH AMERICA ATAXIA MARKET, BY DOSAGE FORM 131

10.1 OVERVIEW 132
10.2 SOLID 135
- 10.2.1 TABLETS 135
- 10.2.2 CAPSULES 136
- 10.2.3 OTHERS 136
10.3 LIQUIDS 136
- 10.3.1 INJECTION 137
- 10.3.2 SOLUTIONS 137
- 10.3.3 OTHERS 137
10.4 OTHERS 137

11 NORTH AMERICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION 139

11.1 OVERVIEW 140
11.2 ORAL 143
11.3 PARENTERAL 143
11.4 OTHERS 144

12 NORTH AMERICA ATAXIA MARKET, BY PATIENT TYPE 145

12.1 OVERVIEW 146
12.2 ADULT 149
- 12.2.1 MALE 149
- 12.2.2 FEMALE 150
12.3 CHILD 150
12.4 GERIATRIC 150

13 NORTH AMERICA ATAXIA MARKET, BY END USER 152

13.1 OVERVIEW 153
13.2 HOSPITAL 156
13.3 CLINICS 156
13.4 HOME HEALTHCARE 157
13.5 OTHERS 157

14 NORTH AMERICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL 159

14.1 OVERVIEW 160
14.2 DIRECT TENDER 163
14.3 RETAIL SALES 163
- 14.3.1 HOSPITAL PHARMACY 164
- 14.3.2 RETAIL SHOP 164
- 14.3.3 ONLINE PHARMACY 164
14.4 OTHERS 164

15 NORTH AMERICA ATAXIA MARKET, BY GEOGRAPHY 166

15.1 NORTH AMERICA 167
- 15.1.1 U.S. 178
- 15.1.2 CANADA 184
- 15.1.3 MEXICO 190

16 NORTH AMERICA ATAXIA MARKET: COMPANY LANDSCAPE 196

16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 196

17 SWOT ANALYSIS 197

18 COMPANY PROFILE 198

18.1 SELECT MEDICAL CORPORATION 198
- 18.1.1 COMPANY SNAPSHOT 198
- 18.1.2 REVENUE ANALYSIS 198
- 18.1.3 COMPANY SHARE ANALYSIS 199
- 18.1.4 PRODUCT PORTFOLIO 199
- 18.1.5 RECENT DEVELOPMENTS 199
18.2 PFIZER INC. 200
- 18.2.1 COMPANY SNAPSHOT 200
- 18.2.2 REVENUE ANALYSIS 200
- 18.2.3 COMPANY SHARE ANALYSIS 201
- 18.2.4 PRODUCT PORTFOLIO 201
- 18.2.5 RECENT DEVELOPMENTS 202
18.3 NOVARTIS AG 203
- 18.3.1 COMPANY SNAPSHOT 203
- 18.3.2 REVENUE ANALYSIS 203
- 18.3.3 COMPANY SHARE ANALYSIS 204
- 18.3.4 PRODUCT PORTFOLIO 204
- 18.3.5 RECENT DEVELOPMENT 204
18.4 AMNEAL PHARMACEUTICALS LLC. 205
- 18.4.1 COMPANY SNAPSHOT 205
- 18.4.2 REVENUE ANALYSIS 205
- 18.4.3 COMPANY SHARE ANALYSIS 206
- 18.4.4 PRODUCT PORTFOLI 206
- 18.4.5 RECENT DEVELOPMENT 206
18.5 UPSTREAM REHABILITATION INC. 207
- 18.5.1 COMPANY SNAPSHOT 207
- 18.5.2 COMPANY SHARE ANALYSIS 207
- 18.5.3 PRODUCT PORTFOLIO 208
- 18.5.4 RECENT DEVELOPMENT 208
18.6 PRIORY 209
- 18.6.1 COMPANY SNAPSHOT 209
- 18.6.2 COMPANY SHARE ANALYSIS 209
- 18.6.3 PRODUCT PORTFOLIO 209
- 18.6.4 RECENT DEVELOPMENT 209
18.7 ACORDA THERAPEUTICS, INC. 210
- 18.7.1 COMPANY SNAPSHOT 210
- 18.7.2 REVENUE ANALYSIS 210
- 18.7.3 PRODUCT PORTFOLIO 211
- 18.7.4 RECENT DEVELOPMENTS 211
18.8 ADVERUM BIOTECHNOLOGIES, INC. 212
- 18.8.1 COMPANY SNAPSHOT 212
- 18.8.2 PRODUCT PORTFOLIO 212
- 18.8.3 RECENT DEVELOPMENT 212
18.9 APOTEX INC. 213
- 18.9.1 COMPANY SNAPSHOT 213
- 18.9.2 PRODUCT PORTFOLIO 213
- 18.9.3 RECENT DEVELOPMENT 213
18.10 ATI PHYSICAL THERAPY 214
- 18.10.1 COMPANY SNAPSHOT 214
- 18.10.2 PRODUCT PORTFOLIO 214
- 18.10.3 RECENT DEVELOPMENT 214
18.11 AUROBINDO PHARMA 215
- 18.11.1 COMPANY SNAPSHOT 215
- 18.11.2 REVENUE ANALYSIS 215
- 18.11.3 PRODUCT PORTFOLIO 216
- 18.11.4 RECENT DEVELOPMENT 216
18.12 BANNER HEALTH 217
- 18.12.1 COMPANY SNAPSHOT 217
- 18.12.2 PRODUCT PORTFOLIO 217
- 18.12.3 RECENT DEVELOPMENT 217
18.13 BIOHAVEN PHARMACEUTICALS 218
- 18.13.1 COMPANY SNAPSHOT 218
- 18.13.2 REVENUE ANALYSIS 218
- 18.13.3 PRODUCT PORTFOLIO 219
- 18.13.4 RECENT DEVELOPMENTS 219
18.14 BIOVISTA 220
- 18.14.1 COMPANY SNAPSHOT 220
- 18.14.2 PRODUCT PORTFOLIO 220
- 18.14.3 RECENT DEVELOPMENT 220
18.15 CIPLA INC. 221
- 18.15.1 COMPANY SNAPSHOT 221
- 18.15.2 REVENUE ANALYSIS 221
- 18.15.3 PRODUCT PORTFOLIO 222
- 18.15.4 RECENT DEVELOPMENT 222
18.16 DESIGN THERAPEUTICS, INC. 223
- 18.16.1 COMPANY SNAPSHOT 223
- 18.16.2 PRODUCT PORTFOLIO 223
- 18.16.3 RECENT DEVELOPMENT 223
18.17 INTRABIO 224
- 18.17.1 COMPANY SNAPSHOT 224
- 18.17.2 PRODUCT PORTFOLIO 224
- 18.17.3 RECENT DEVELOPMENT 224
18.18 LUPIN. 225
- 18.18.1 COMPANY SNAPSHOT 225
- 18.18.2 REVENUE ANALYSIS 225
- 18.18.3 PRODUCT PORTFOLIO 226
- 18.18.4 RECENT DEVELOPMENTS 226
18.19 MATRIX BIOMED 227
- 18.19.1 COMPANY SNAPSHOT 227
- 18.19.2 PRODUCT PORTFOLIO 227
- 18.19.3 RECENT DEVELOPMENT 227
18.20 MERCK KGAA 228
- 18.20.1 COMPANY SNAPSHOT 228
- 18.20.2 REVENUE ANALYSIS 228
- 18.20.3 PRODUCT PORTFOLIO 228
18.20 RECENT DEVELOPMENTS 229
18.21 REATA PHARMACEUTICALS, INC. 230
- 18.21.1 COMPANY SNAPSHOT 230
- 18.21.2 PRODUCT PORTFOLIO 230
- 18.21.3 RECENT DEVELOPMENT 230
18.22 RETROTOPE INC. 231
- 18.22.1 COMPANY SNAPSHOT 231
- 18.22.2 PRODUCT PORTFOLIO 231
- 18.22.3 RECENT DEVELOPMENT 231
18.23 SANOFI 232
- 18.23.1 COMPANY SNAPSHOT 232
- 18.23.2 REVENUE ANALYSIS 232
- 18.23.3 PRODUCT PORTFOLIO 232
- 18.23.4 RECENT DEVELOPMENT 233
18.24 SUN PHARMACEUTICAL INDUSTRIES LTD. 234
- 18.24.1 COMPANY SNAPSHOT 234
- 18.24.2 REVENUE ANALYSIS 234
- 18.24.3 PRODUCT PORTFOLIO 235
- 18.24.4 RECENT DEVELOPMENT 235
18.25 SUTTER HEALTH 236
- 18.25.1 COMPANY SNAPSHOT 236
- 18.25.2 PRODUCT PORTFOLIO 236
- 18.25.3 RECENT DEVELOPMENTS 237
18.26 TEVA PHARMACEUTICAL INDUSTRIES LTD. 238
- 18.26.1 COMPANY SNAPSHOT 238
- 18.26.2 REVENUE ANALYSIS 238
- 18.26.3 PRODUCT PORTFOLIO 239
- 18.26.4 RECENT DEVELOPMENT 239
18.27 VIATRIS INC. 240
- 18.27.1 COMPANY SNAPSHOT 240
- 18.27.2 REVENUE ANALYSIS 240
- 18.27.3 PRODUCT PORTFOLIO 241
- 18.27.4 RECENT DEVELOPMENT 241

19 QUESTIONNAIRE 242

20 RELATED REPORTS 245

LIST OF TABLES

TABLE 1 NORTH AMERICA ATAXIA MARKET: PIPELINE ANALYSIS 47
TABLE 2 NORTH AMERICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND) 62
TABLE 3 NORTH AMERICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 63
TABLE 4 NORTH AMERICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND) 64
TABLE 5 NORTH AMERICA ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 65
TABLE 6 NORTH AMERICA EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 66
TABLE 7 NORTH AMERICA OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 67
TABLE 8 NORTH AMERICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 71
TABLE 9 NORTH AMERICA TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 73
TABLE 10 NORTH AMERICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 73
TABLE 11 NORTH AMERICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 74
TABLE 12 NORTH AMERICA STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 74
TABLE 13 NORTH AMERICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 75
TABLE 14 NORTH AMERICA ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 76
TABLE 15 NORTH AMERICA NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 77
TABLE 16 NORTH AMERICA ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 78
TABLE 17 NORTH AMERICA ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 79
TABLE 18 NORTH AMERICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 80
TABLE 19 NORTH AMERICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 80
TABLE 20 NORTH AMERICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 81
TABLE 21 NORTH AMERICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 82
TABLE 22 NORTH AMERICA DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 83
TABLE 23 NORTH AMERICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 84
TABLE 24 NORTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 84
TABLE 25 NORTH AMERICA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 88
TABLE 26 NORTH AMERICA SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 89
TABLE 27 NORTH AMERICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 89
TABLE 28 NORTH AMERICA LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 90
TABLE 29 NORTH AMERICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 91
TABLE 30 NORTH AMERICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 92
TABLE 31 NORTH AMERICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND) 96
TABLE 32 NORTH AMERICA ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 97
TABLE 33 NORTH AMERICA PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 98
TABLE 34 NORTH AMERICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 98
TABLE 35 NORTH AMERICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND) 102
TABLE 36 NORTH AMERICA ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 103
TABLE 37 NORTH AMERICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND) 103
TABLE 38 NORTH AMERICA CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 104
TABLE 39 NORTH AMERICA GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 105
TABLE 40 NORTH AMERICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND) 109
TABLE 41 NORTH AMERICA HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 110
TABLE 42 NORTH AMERICA CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 111
TABLE 43 NORTH AMERICA HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 111
TABLE 44 NORTH AMERICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 112
TABLE 45 NORTH AMERICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND) 116
TABLE 46 NORTH AMERICA DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 117
TABLE 47 NORTH AMERICA RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 118
TABLE 48 NORTH AMERICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND) 118
TABLE 49 NORTH AMERICA OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND) 119
TABLE 50 NORTH AMERICA ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND) 126
TABLE 51 NORTH AMERICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND) 126
TABLE 52 NORTH AMERICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND) 126
TABLE 53 NORTH AMERICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 126
TABLE 54 NORTH AMERICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 126
TABLE 55 NORTH AMERICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 127
TABLE 56 NORTH AMERICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 127
TABLE 57 NORTH AMERICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 127
TABLE 58 NORTH AMERICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 127
TABLE 59 NORTH AMERICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 128
TABLE 60 NORTH AMERICA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 128
TABLE 61 NORTH ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 128
TABLE 62 NORTH AMERICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 128
TABLE 63 NORTH AMERICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 129
TABLE 64 NORTH AMERICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 129
TABLE 65 NORTH AMERICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 129
TABLE 66 NORTH AMERICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 129
TABLE 67 NORTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 130
TABLE 68 NORTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 130
TABLE 69 NORTH AMERICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 130
TABLE 70 NORTH AMERICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 130
TABLE 71 NORTH AMERICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND) 130
TABLE 72 NORTH AMERICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND) 131
TABLE 73 NORTH AMERICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND) 131
TABLE 74 NORTH AMERICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND) 131
TABLE 75 NORTH AMERICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND) 131
TABLE 76 NORTH AMERICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND) 131
TABLE 77 U.S. ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND) 132
TABLE 78 U.S. SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND) 132
TABLE 79 U.S. ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 132
TABLE 80 U.S. TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 132
TABLE 81 U.S. PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 133
TABLE 82 U.S. STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 133
TABLE 83 U.S. GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 133
TABLE 84 U.S. ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 133
TABLE 85 U.S. NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 134
TABLE 86 U.S. ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 134
TABLE 87 U.S. ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 134
TABLE 88 U.S. ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 134
TABLE 89 U.S. SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 135
TABLE 90 U.S. LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 135
TABLE 91 U.S. SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 135
TABLE 92 U.S. DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 135
TABLE 93 U.S. IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 135
TABLE 94 U.S. IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 136
TABLE 95 U.S. SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 136
TABLE 96 U.S. LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 136
TABLE 97 U.S. ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND) 136
TABLE 98 U.S. ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND) 136
TABLE 99 U.S. ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND) 137
TABLE 100 U.S. ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND) 137
TABLE 101 U.S. ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND) 137
TABLE 102 U.S. RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND) 137
TABLE 103 CANADA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND) 138
TABLE 104 CANADA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND) 138
TABLE 105 CANADA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 138
TABLE 106 CANADA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 138
TABLE 107 CANADA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 139
TABLE 108 CANADA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 139
TABLE 109 CANADA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 139
TABLE 110 CANADA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 139
TABLE 111 CANADA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 140
TABLE 112 CANADA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 140
TABLE 113 CANADA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 140
TABLE 114 CANADA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 140
TABLE 115 CANADA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 141
TABLE 116 CANADA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 141
TABLE 117 CANADA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 141
TABLE 118 CANADA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 141
TABLE 119 CANADA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 141
TABLE 120 CANADA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 142
TABLE 121 CANADA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 142
TABLE 122 CANADA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 142
TABLE 123 CANADA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND) 142
TABLE 124 CANADA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND) 142
TABLE 125 CANADA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND) 143
TABLE 126 CANADA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND) 143
TABLE 127 CANADA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND) 143
TABLE 128 CANADA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND) 143
TABLE 129 MEXICO ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND) 144
TABLE 130 MEXICO SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND) 144
TABLE 131 MEXICO ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 144
TABLE 132 MEXICO TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 144
TABLE 133 MEXICO PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 145
TABLE 134 MEXICO STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 145
TABLE 135 MEXICO GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 145
TABLE 136 MEXICO ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 145
TABLE 137 MEXICO NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 146
TABLE 138 MEXICO ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 146
TABLE 139 MEXICO ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 146
TABLE 140 MEXICO ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 146
TABLE 141 MEXICO SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 147
TABLE 142 MEXICO LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 147
TABLE 143 MEXICO SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 147
TABLE 144 MEXICO DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 147
TABLE 145 MEXICO IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND) 147
TABLE 146 MEXICO IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 148
TABLE 147 MEXICO SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 148
TABLE 148 MEXICO LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND) 148
TABLE 149 MEXICO ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND) 148
TABLE 150 MEXICO ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND) 148
TABLE 151 MEXICO ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND) 149
TABLE 152 MEXICO ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND) 149
TABLE 153 MEXICO ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND) 149
TABLE 154 MEXICO RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND) 149

LIST OF FIGURES

FIGURE 1 NORTH AMERICA ATAXIA MARKET: SEGMENTATION 26
FIGURE 2 NORTH AMERICA ATAXIA MARKET: DATA TRIANGULATION 29
FIGURE 3 NORTH AMERICA ATAXIA MARKET: DROC ANALYSIS 30
FIGURE 4 NORTH AMERICA ATAXIA MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 31
FIGURE 5 NORTH AMERICA ATAXIA MARKET: COMPANY RESEARCH ANALYSIS 31
FIGURE 6 NORTH AMERICA ATAXIA MARKET: INTERVIEW DEMOGRAPHICS 33
FIGURE 7 NORTH AMERICA ATAXIA MARKET: DBMR MARKET POSITION GRID 34
FIGURE 8 NORTH AMERICA ATAXIA MARKET: END USER COVERAGE GRID 35
FIGURE 9 NORTH AMERICA ATAXIA MARKET: VENDOR SHARE ANALYSIS 36
FIGURE 10 NORTH AMERICA ATAXIA MARKET: SEGMENTATION 40
FIGURE 11 RAPID RESEARCH IN FIELD OF ATAXIA THEREPEUTICS IS EXPECTED TO DRIVE THE NORTH AMERICA ATAXIA MARKET IN THE FORECAST PERIOD 41
FIGURE 12 SPINOCEREBELLAR ATAXIAS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ATAXIA MARKET IN 2022 & 2029 41
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA ATAXIA MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 42
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA ATAXIA MARKET 52
FIGURE 15 NORTH AMERICA ATAXIA MARKET: BY TYPE, 2021 59
FIGURE 16 NORTH AMERICA ATAXIA MARKET: BY TYPE, 2022-2029 (USD THOUSAND) 60
FIGURE 17 NORTH AMERICA ATAXIA MARKET: BY TYPE, CAGR (2022-2029) 60
FIGURE 18 NORTH AMERICA ATAXIA MARKET: BY TYPE, LIFELINE CURVE 61
FIGURE 19 NORTH AMERICA ATAXIA MARKET: BY PRODUCT, 2021 68
FIGURE 20 NORTH AMERICA ATAXIA MARKET: BY PRODUCT, 2022-2029 (USD THOUSAND) 69
FIGURE 21 NORTH AMERICA ATAXIA MARKET: BY PRODUCT, CAGR (2022-2029) 69
FIGURE 22 NORTH AMERICA ATAXIA MARKET: BY PRODUCT, LIFELINE CURVE 70
FIGURE 23 NORTH AMERICA ATAXIA MARKET: BY DOSAGE FORM, 2021 85
FIGURE 24 NORTH AMERICA ATAXIA MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND) 86
FIGURE 25 NORTH AMERICA ATAXIA MARKET: BY DOSAGE FORM, CAGR (2022-2029) 86
FIGURE 26 NORTH AMERICA ATAXIA MARKET: BY DOSAGE FORM, LIFELINE CURVE 87
FIGURE 27 NORTH AMERICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2021 93
FIGURE 28 NORTH AMERICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND) 94
FIGURE 29 NORTH AMERICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 94
FIGURE 30 NORTH AMERICA ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 95
FIGURE 31 NORTH AMERICA ATAXIA MARKET: BY PATIENT TYPE, 2021 99
FIGURE 32 NORTH AMERICA ATAXIA MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND) 100
FIGURE 33 NORTH AMERICA ATAXIA MARKET: BY PATIENT TYPE, CAGR (2022-2029) 100
FIGURE 34 NORTH AMERICA ATAXIA MARKET: BY PATIENT TYPE, LIFELINE CURVE 101
FIGURE 35 NORTH AMERICA ATAXIA MARKET: BY END USER, 2021 106
FIGURE 36 NORTH AMERICA ATAXIA MARKET: BY END USER, 2022-2029 (USD THOUSAND) 107
FIGURE 37 NORTH AMERICA ATAXIA MARKET: BY END USER, CAGR (2022-2029) 107
FIGURE 38 NORTH AMERICA ATAXIA MARKET: BY END USER, LIFELINE CURVE 108
FIGURE 39 NORTH AMERICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2021 113
FIGURE 40 NORTH AMERICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND) 114
FIGURE 41 NORTH AMERICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 114
FIGURE 42 NORTH AMERICA ATAXIA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 115
FIGURE 43 NORTH AMERICA ATAXIA MARKET: SNAPSHOT (2021) 121
FIGURE 44 NORTH AMERICA ATAXIA MARKET: BY COUNTRY (2021) 123
FIGURE 45 NORTH AMERICA ATAXIA MARKET: BY COUNTRY (2022 & 2029) 123
FIGURE 46 NORTH AMERICA ATAXIA MARKET: BY COUNTRY (2021 & 2029) 124
FIGURE 47 NORTH AMERICA ATAXIA MARKET: BY TYPE (2022-2029) 124
FIGURE 48 NORTH AMERICA ATAXIA MARKET: COMPANY SHARE 2021 (%) 149